1. Introduction {#s1}
===============

Heart failure (HF) is a common disease in older adults and, as a consequence, also highly prevalent in nursing home residents.[@b1],[@b2] Adequate treatment of HF may not only lead to reduced mortality and hospital admissions, but it may also relieve symptoms, lead to improvement in quality of life and increase functional capacity.[@b3],[@b4] According to the current guidelines of the European Society of Cardiology and the American College of Cardiology/American Heart Association, both pharmacological and non-pharmacological therapies should be employed in HF patients.[@b5],[@b6] The pharmacological treatment depends on the type of HF. Pharmacological treatment of HF in patients with reduced ejection fraction is clearly described, whereas, for HF with preserved ejection fraction, there is no evidenced pharmacological therapy available.[@b5],[@b6] Every HF patient with reduced ejection fraction should receive an angiotensin converting enzyme (ACE)-inhibitor and, thereafter, also a β-blocker as soon as possible. A diuretic could be necessary to control fluid overload. For HF with preserved ejection fraction, adequate treatment of underlying diseases and symptoms, such as hypertension, myocardial ischaemia and oedema, is recommended. Non-pharmacological interventions consist of life style changes such as fluid- and sodium-restriction, daily weighing, adjustment of activity, vaccination against influenza, smoking cessation and limitation of the amount of alcohol ingested.[@b7]

Nursing home residents are frail, disabled, older adults with high levels of care dependency, who are mostly excluded from clinical and epidemiological studies.[@b8] Despite that, recommendations regarding diagnostics and therapeutic interventions do not differ depending on age.[@b5] Therefore, nursing home residents should be treated similarly to other patients, but previous studies conclude that this is often not the case. In a review of Litaker, 13 studies (published between 1991 and 2002) concerning the pharmacological treatment of HF in elderly nursing home residents were analysed with an overall conclusion that nursing home residents with HF did not receive pharmacological treatment according to the guidelines.[@b9] In addition, more recent studies in Sweden, Poland and the United States have demonstrated that the treatment of patients with HF in nursing homes and long-term care facilities is still not in accordance with current guidelines.[@b10]--[@b12] Unfortunately, it has not been properly investigated whether the recommendations for non-pharmacological HF treatment as described in the guidelines are also applied to nursing home residents. However, non-pharmacological treatment can have a positive impact on symptoms, functional capacity, well-being, morbidity and prognosis.[@b13] The aim of this study was to investigate how nursing home residents with HF are treated pharmacologically and non-pharmacologically in Dutch nursing homes. In particular, we determined to what extent the actual treatment corresponded with current international HF guidelines.[@b5],[@b6]

2. Methods {#s2}
==========

This study followed a multi-center cross-sectional design and was nested in a larger study on HF in nursing home residents described in a previously published study protocol.[@b14] The study complied with the Declaration of Helsinki and has been granted approval from the Medical Ethics Committee of Maastricht University/Academic Hospital Maastricht (NL33281.068.10/MEC10-3-074). The study is registered in the Dutch trial register (NTR2663).

2.1. Setting and sample {#s2a}
-----------------------

Nursing home residents in the southern part of the Netherlands allocated to five large long-term care organizations were recruited to participate. In the Netherlands, nursing homes provide a high-level of nursing, medical and paramedical care to frail older adults with chronic diseases and disabilities that are either physical or mental in nature (mainly dementia), or both.[@b15]

Five hundred and one residents over 65 years of age, who received long-term care on somatic or psychogeriatric wards, were eligible for participating in the larger study. Only residents with a diagnosis of HF in the medical record were included in this study, irrespective of how the diagnosis was made or who made it. In most patients, this meant that left-ventricular ejection fraction (LVEF) was not known. Patients with the diagnosis of HF were compared with those not having a diagnosis of HF. Data were gathered within a specified time period (January 2011 to June 2013). Informed consent for participating was obtained from the residents themselves or from their legal representatives in the case of psychogeriatric residents, or residents with aphasia.

2.2. Measurements and materials {#s2b}
-------------------------------

Patients\' characteristics were collected in all participating residents including age, gender, receiving psychogeriatric or somatic nursing home care, symptoms, cardiac history, co-morbidities, and cardiovascular risk factors. These predetermined variables of demographic data, cardiac history, co-morbidities and cardiovascular risk factors were obtained from medical records and registered on a case record file (CRF) by a research nurse. A nursing home physician, who had received a refresher course in diagnosing HF, was responsible for assessment of symptoms of HF on the CRF.

Regarding the pharmacological treatment, cardiac medications \[diuretics, ACE-inhibitors, β-blockers and angiotensin receptor blocker (ARB) antagonists\] as prescribed and processed by the pharmacist on the medication list were registered. Regarding non-pharmacological interventions, fluid restriction (\< 1.5 L/day), sodium restriction (max 2.5 g/day), physiotherapy residents themselves or the nursing staff (in case of dementia or aphasia) were questioned about whether interventions were applied. After inclusion, participating residents underwent an echocardiography. A LVEF of ≤ 40% was considered as reduced ejection fraction.[@b5],[@b6]

2.3. Statistical analyses {#s2c}
-------------------------

Statistical analyzes were performed using IBM SPSS statistics software version 22. Data are presented as frequencies or mean ± SD as appropriate. Differences between groups were tested using Student\'s *t*-tests for continuous (dependent) variables and Chi-square tests (cross-table analysis) for discrete variables.

3. Results {#s3}
==========

Of the 501 residents included in the main study, 112 were previously diagnosed with HF based on their medical records. The characteristics of the patients with and without the diagnosis of HF are shown in [Table 1](#jgc-13-01-044-t01){ref-type="table"}. In 15 residents, there were missing echocardiography results caused by poor image quality due to obesity or chronic obstructive pulmonary disease (COPD) and/or resistance to the echocardiography mainly by psychogeriatric residents. Of the remaining residents (*n* = 97) with a diagnosis of HF 22 residents (20%) had a LVEF ≤ 40%. When comparing the two groups of residents with and without HF, residents with HF had more complaints of dyspnea shown by the percentages of the New York Heart Association classes. Peripheral edema was highly prevalent in both groups. There was a significantly higher prevalence of cardiovascular diseases, except for hypertension, in residents with HF. COPD was more prevalent in residents with HF compared to those without HF. The mean blood pressure (systolic and diastolic) was lower in residents with HF as compared to those without.

###### Clinical characteristics of the study population.

  Variables                                                No HF recorded, *n* = 389   Diagnosed with HF, *n* = 112   *P*-value
  ------------------------------------------------------- --------------------------- ------------------------------ -----------
  Age, yrs                                                          82 ± 7                        83 ± 7                0.114
  Gender, male                                                     131 (34%)                     48 (43%)               0.074
  Psychogeriatric                                                  259 (67%)                     67 (60%)               0.186
  NYHA-class                                                                                                         
   Class I                                                         260 (67%)                     47 (41%)             \< 0.001
   Class II                                                        74 (19%)                      34 (31%)               0.023
   Class III                                                        36 (9%)                      21 (29%)               0.014
   Class IV                                                         19 (5%)                       9 (8%)                0.336
  Symptoms                                                                                                           
   Edema                                                           203 (52%)                     72 (64%)               0.018
   Orthopnea                                                       38 (10%)                      24 (21%)             \< 0.001
  Cardiac history                                                                                                    
   Hypertension                                                    181 (47%)                     55 (49%)               0.63
   Myocardial infarction                                           51 (13%)                      30 (27%)               0.001
   Arrhythmia                                                      60 (15%)                      39 (35%)             \< 0.001
   Coronary ischaemia                                              73 (19%)                      40 (36%)               0.001
   Valvular heart disease                                           20 (5%)                      18 (16%)               0.001
   Coronary bypass graft                                            27 (7%)                      13 (12%)               0.275
   Pace maker                                                       13 (3%)                       6 (5%)                0.603
  Co-morbidity                                                                                                       
   Diabetes mellitus                                               79 (20%)                      28 (25%)               0.286
   COPD                                                            51 (13%)                      32 (29%)             \< 0.001
   CVA                                                             162 (42%)                     45 (40%)               0.781
   Renal insufficiency, eGFR \< 60 mL/min per 1.73 m^2^            106 (27%)                     56 (50%)             \< 0.001
   Anaemia                                                         114 (29%)                     43 (38%)               0.058
  Cardiac risk factors                                                                                               
   BMI, kg/m^2^                                                     25 ± 5                        26 ± 5                0.224
   Hypercholesterolaemia                                           105 (27%)                     25 (22%)               0.520
   Smoking                                                         54 (14%)                      14 (13%)               0.931
   Heart rate, beats/min                                            73 ± 13                      73 ± 15                0.921
   Systolic blood pressure, mmHg                                   142 ± 24                      132 ± 29             \< 0.001
   Diastolic blood pressure, mmHg                                   76 ± 14                      72 ± 15                0.026
   Creatinine, µmol/L                                               83 ± 45                      102 ± 66               0.001
  Echocardiography                                                                                                   
   LVEF, *n* = 405                                                 56% ± 11%                    52% ± 14%               0.001
   LVEF \> 40%                                                     276 (71%)                     75 (67%)               0.002
   LVEF ≤ 40%                                                       32 (8%)                      22 (20%)            
   Unknown                                                         81 (21%)                      15 (13%)            

Data are presented as mean ± SD or *n* (%). BMI: body mass index; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accidents; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association.

3.1. Pharmacological and non-pharmacological treatment of HF {#s3a}
------------------------------------------------------------

An overview of the pharmacological and non-pharmacological treatment is presented in [Table 2](#jgc-13-01-044-t02){ref-type="table"}. 46% of the residents with an LVEF ≤ 40% used an ACE-inhibitor and 64% a β-blocker. Diuretics were prescribed in two thirds of the residents diagnosed with HF. Only one third of residents with a reduced ejection fraction received a combination of an ACE-inhibitor/ARB-antagonist and a β-blocker. Spironolactone was prescribed in only a minority of patients, irrespective of LVEF.

Non-pharmacological treatment, such as fluid-restriction, sodium-restriction or physiotherapy, was recorded in 5% or less of the residents. Many more patients without the diagnosis of HF received physiotherapy as compared to nearly none with HF.

3.2. Prescribed cardiac medication {#s3b}
----------------------------------

As shown in [Table 3](#jgc-13-01-044-t03){ref-type="table"}, there was no preference for the use of a specific ACE-inhibitor in our patient population with HF. The median daily doses of ACE-inhibitors and ARBs were lower than those recommended by the guidelines.

For the β-blockers, metoprolol was the drug of preference with a median dose of 87 mg, which is \< 50% of the target dose stated in the guidelines. Loop diuretics were the medication of choice if patients received diuretic therapy. The median daily dose varies per drug in both LVEF ≤ 40% as LVEF \> 40%.

4. Discussion {#s4}
=============

In our group of nursing home residents with the previous diagnosis of heart failure, the recommended medical therapy for HF was often not prescribed and, if prescribed, dosage was usually far below what was recommended by the guidelines, whereas non-pharmacological interventions were rarely used.

The prescription of an ACE-inhibitor in 30% of the residents with HF irrespective of the LVEF was in line with the results presented in the review by Litaker, where the prevalence of ACE-inhibitor use ranged from 21%--35%.[@b9] A more recent publication by Hancock showed a use of 44% in residents with a reduced LVEF and 26% in residents with a preserved LVEF.[@b1] This was also seen in the study of Foreman, where all participating residents had a LVEF ≤ 40%, and 35% of the residents used an ACE-inhibitor.[@b16] These findings are similar to our findings, showing an underuse of ACE-inhibitors in our nursing home residents. Although there is only an evidence based treatment of HF with a reduced EF, previous studies did not find major differences in the prescription rate of cardiac medication in patients with reduced LVEF as compared to preserved LVEF.[@b17],[@b18] This is also demonstrated in this study.

###### Pharmacological and non-pharmacological treatment of HF in nursing home residents.

                                                   No HF     Diagnosed with HF                        
  --------------------------------------------- ----------- ------------------- ---------- ---------- ----------
  Pharmacological treatment                                                                           
   Diuretics                                     117 (30%)       74 (66%)        18 (82%)   45 (60%)   11 (73%)
   β-blocker                                     112 (29%)       44 (39%)        14 (64%)   24 (32%)   6 (40%)
   ACE-inhibitor                                 59 (15%)        33 (30%)        10 (46%)   20 (27%)   3 (20%)
   ARB-antagonist                                46 (12%)         7 (6%)          2 (9%)     3 (4%)    2 (13%)
   Spironolactone                                 7 (2%)         18 (16%)        3 (14%)    11 (15%)   4 (27%)
   ACE-inhibitor and ARB antagonist                                  1              1                 
   ACE-inhibitor/ARB antagonist and β-blocker    43 (11%)        19 (17%)        8 (36%)    8 (11%)     1 (7%)
   β-blocker and diuretics                       47 (12%)        32 (29%)        12 (55%)   16 (21%)   5 (33%)
   ACE-inhibitor/ARB antagonist and diuretics    45 (12%)        34 (30%)        8 (36%)    17 (23%)   5 (33%)
   ^a^Trias medication                            16 (4%)        17 (15%)        8 (36%)    8 (11%)     1 (7%)
  Non-pharmacological treatment                                                                       
   Fluid-restriction, 1.5 L/day                   4 (1%)          6 (5%)                              
   Sodium-restriction, 2.5 g/day                  3 (1%)          4 (4%)                              
   Physiotherapy/activity training               171 (44%)        1 (1%)                              

Data are presented as *n* (%). ^a^Trias medication = ACE-inhibitor/ARB-antagonist and β-blocker and diuretics; ^b^Information of echocardiography available in *n* = 97 residents. ACE: angiotensin converting enzym; ARB: angiotensin receptor blocker; HF: heart failure; LVEF: left ventricle ejection fraction.

###### Prescribed cardiac medication in nursing home residents with HF.

                          Diagnosis of HF \[*n* (%), *n* = 112\]   Median daily dose (mg, *n* = 112)   Range (mg)   Median daily dose in mg based on LVEF   Maximum doses in ACCF/AHA, mg/day   Target dose in ESC, mg/day        
  ---------------------- ---------------------------------------- ----------------------------------- ------------ --------------------------------------- ----------------------------------- ---------------------------- ----- ---------
  Diuretics                             \*74 (66%)                                                                                                                                                                                
   Hydrochlorothiazide                    5 (5%)                                  15                     12--25                      15                                    \-                               25               200  
   Furosemide                            47 (42%)                                 44                    20--160                      46                                    38                               35               600  
   Bumetanide                            21 (19%)                                 2.6                    1--12                       2,6                                   2,9                              1                10   
   Spironolactone                        18 (16%)                                 30                    12.5--50                     30                                    25                               31               50    25--50
  β-blocker                              44 (39%)                                                                                                                                                                                 
   Bisoprolol                             4 (4%)                                 3.75                    2.5--5                     3,75                                    5                              2.5               10      10
   Carvedilol                             5 (5%)                                 43.75                 6.25--150                    6,25                                   67                              12.5              100   50--100
   Metoprolol                            30 (27%)                                 87                    25--200                      86                                    81                              100               200     200
   Nebivolol                              1 (1%)                                   5                                                  5                                    \-                               \-                       10
   Sotalol                                4 (4%)                                  100                   40--160                      140                                   60                               \-                    
  ACE-inhibitor                          33 (30%)                                                                                                                                                                                 
   Quinapril                              8 (7%)                                 8.75                    5--20                        5                                    11                               \-               40   
   Perindopril                            9 (8%)                                   3                      2--5                        3                                     2                               \-               16   
   Fosinopril                             3 (3%)                                  20                     10--40                      40                                    10                               10               40   
   Captopril                              5 (5%)                                  50                   12.5--125                     58                                    50                               25               150     150
   Enalapril                              5 (5%)                                  11                     5--20                       11                                    \-                               \-               40    20--40
   Lisinopril                             3 (3%)                                 17.5                   2.5--40                      25                                    40                               10               40    20--35
  ARB-antagonist                          6 (6%)                                                                                                                                                                                  
   Irbesartan                             2 (2%)                                  225                   150--300                     150                                   \-                              300                    
   Losartan                               4 (4%)                                 58.75                   5--100                     37,5                                  62,5                              \-               150     150

ACCF/AHA: American College of Cardiology Foundation/American Heart Association; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; ESC: European Society of Cardiology; HF: heart failure; LVEF: left ventricle ejection fraction. \**N* = 17 used a combination of two diuretics.

A possible reason for the underuse might be that residents were at a greater risk for adverse drug reactions, such as renal dysfunction and hypotension due to polypharmacy and co-morbidity.[@b18],[@b19] However, we do not have any information to what extent this might have explained the underuse seen in our study. In addition, average renal function was not severely reduced. Another explanation for the underuse of treatment with ACE-inhibitors could be that the time of onset of HF is not always obvious and, as a result, no medication adjustment as recommended by the guidelines occurs.

Although β-blocker use was 64% in residents with HF and LVEF ≤ 40%, only 36% of these residents received a combination of a β-blocker with an ACE-inhibitor or ARB-antagonist. In the studies by Bolmsjo and Hancock, 59% and 30%, respectively, of the residents used a β-blocker.[@b1],[@b10] Compared to the early 2000s, this seems to be a positive development in the use of β-blockers. As in the studies by Ruths and Lien, only 3 (*n* = 1552) and 5 (*n* = 116) residents, respectively, used a β-blocker.[@b20],[@b21] However, it might be that this increase in the use of β-blockers is not only a consequence of a better compliance with the guidelines to treat HF, but also the result of prescribing a β-blocker due to another indication. These other indications, such as hypertension, CAD or arrhythmia are also very prevalent in our nursing home population. In addition, focusing on morbidity and mortality, the SENIORS study investigated the effect of nebivolol, and found that it was well tolerated and effective in reducing mortality and morbidity in patients \> 70 years old, regardless of the ejection fraction.[@b22] It is remarkable that, in our study, only one resident used nebivolol. Studies on other β-blockers in HF, such as the drug of preference, metoprolol, included much younger patient populations.[@b23]

In our study, loop diuretics were the most frequently used therapeutics for residents with HF, as seen in many other cohort studies, particularly in elderly patients.[@b24] A relatively high rate of diuretic use is expected because diuretics are recommended for symptomatic treatment of fluid overload irrespective of LVEF. Still, it is noteworthy that a significant proportion of patients without the diagnosis of HF also received diuretics and had peripheral edema.

This study showed that, in almost none of the residents, the recommended daily target dose of cardiac medication was achieved. Comparing the median daily dose by LVEF, a higher median daily dose in residents with LVEF ≤ 40% might be expected. However on average, this was not the case. Given the low rate of HF specific treatment, this may be seen as not surprising knowing that nursing home residents are at a greater risk for adverse drug reactions due to polypharmacy and co-morbidities.[@b11] Older patients on β-blocker medication have a higher risk of side effects when compared to younger persons, and diuretics could have a negative effect such as the development of the cardio-renal syndrome.[@b25]

An overall reason for not prescribing and/or prescribing cardiac medication in a low dosage could be due to the fact that reducing mortality may be seen as unimportant in nursing home residents, but relieving symptoms and improving quality of life may be seen as even more crucial. It is, however, important to note that the treatment with ACE-inhibitors was not only found to reduce mortality in HF, but also to reduce symptoms and significantly improve quality of life. Although there seems to be no benefit regarding the quality of life by adding a β-blocker or spironolactone, there is still the need for appropriate diagnostics and therapy of HF, given the effects on reducing hospitalisations, taking age into account and the fact that a patient is living in a nursing home.[@b26]

The use of non-pharmacological interventions was nearly absent in our residents. We are not aware of any other studies that described the non-pharmacological treatment in nursing home residents with HF. Non-pharmacological therapy, including exercise training and dietary and life-style advice, showed beneficial effects in relieving symptoms and improving both quality of life and prognosis.[@b7] Several studies showed benefits of exercise in older adults on tiredness and breathlessness that limited daily activities.[@b27],[@b28] Unfortunately, it appears that there is insufficient attention on the benefits of non-pharmacological interventions of HF in nursing home residents, which is an important area of attention for improving HF care in nursing homes. The possible reasons for this discrepancy remain speculative. One could be that nursing home physicians do not have enough knowledge regarding the benefits of non-pharmacological interventions.

There are several limitations of this study. First, the diagnosis of HF was retrieved out of medical records; however in many patients, as is often the case in clinical practice, original records of cardiologic examinations were not available. Thus, LVEF related to the previous diagnosis of HF was not known and we could separate patient groups based on LVEF after inclusion in the study only. Moreover, in some patients, LVEF could not be determined. Furthermore, there was no information available about possible adverse drugs reactions. Thus, we do not understand precise indications of medication in individual patients.

Guidelines assume that the elderly should be treated the same way as the younger patients with HF. However, the guideline treatment of hypertension has demonstrated adjustments of the target values of systolic blood pressure and the TIME-CHF study showed that there were no differences in outcomes for the elderly when HF was treated more intensively, in contrast to the younger patients.[@b29],[@b30] This suggests that, it might be necessary to adjust the guidelines to optimize HF treatment in older adults and more specific nursing home residents, but this should be tested prospectively in appropriate clinical trials.

In conclusion, this study demonstrates that the current pharmacological treatment of nursing home residents with HF was not according to the guidelines specified, and the non-pharmacological treatment was almost absent in nursing residents with HF. The clinical consequences are unknown and require specific studies on this frail population.

None of the authors have any competing interests arising from this research. This work was supported by an unrestricted grant from the Dutch Organization for Health Research and Development (ZonMw), grant number 60-61900-98-303.
